Treatment With Intravitreal Avastin for Large Uveal Melanomas

Status Completed

Clinical Trial Summary

The purpose of this study is to test the safety and effectiveness of Avastin introduced into the inside of the eyeball in causing shrinkage of the uveal melanoma (tumor of the eye). Avastin is an anti-cancer drug specially designed to shrink blood vessels within tumors.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00596362
Study type	Interventional
Source	Memorial Sloan Kettering Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	April 2007
Completion date	June 2008

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04364230` - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)	Phase 1/Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Active, not recruiting	`NCT05542342` - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases.	Phase 2
Completed	`NCT02849145` - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)	N/A
Recruiting	`NCT01438658` - Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma	N/A
Not yet recruiting	`NCT00811200` - Treatment Of Radiation Retinopathy Trial	Phase 2/Phase 3
Completed	`NCT00121225` - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma	Phase 2
Recruiting	`NCT05077280` - A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma	Phase 2
Completed	`NCT03297424` - A Study of PLX2853 in Advanced Malignancies.	Phase 1
Withdrawn	`NCT05482074` - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2	Phase 2
Completed	`NCT04551352` - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas	Phase 1
Not yet recruiting	`NCT06246149` - Adjuvant Tebentafusp in High Risk Ocular Melanoma	Phase 3
Completed	`NCT01955941` - Vascular Response to Brachytherapy Using Functional OCT
Completed	`NCT00661622` - Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF	Phase 2
Recruiting	`NCT05502900` - Adjuvant Melatonin for Uveal Melanoma	Phase 3
Active, not recruiting	`NCT03070392` - Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma	Phase 2
Recruiting	`NCT06284512` - Uveal Melanoma - Comparative Study
Recruiting	`NCT05524935` - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma	Phase 2
Active, not recruiting	`NCT02913417` - Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases	Phase 1/Phase 2
Not yet recruiting	`NCT06073548` - Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study